• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glaukos

Glaukos to exchange $230M in senior notes for common stock

June 14, 2024 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that it entered into exchange agreements to repurchase approximately $230 million. The company entered into separate, privately negotiated exchange agreements with certain holders of 2.75% convertible senior notes due 2027. Pursuant to these agreements, the company agreed to repurchase $230 million of existing convertible notes for aggregate consideration of shares of […]

Filed Under: Business/Financial News, Funding Roundup, Implants, Optical/Ophthalmic Tagged With: Glaukos

FDA approves Glaukos iDose TR glaucoma-treating drug delivery implant

December 14, 2023 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) announced today that the FDA approved a New Drug Application (NDA) for its iDose TR implant. The approval allows for one administration per eye of iDose TR (travoprost intracameral implant) 75 mcg. The indication for the prostaglandin analog covers the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: FDA, Glaukos

Celanese to provide drug delivery platform for Glaukos glaucoma treatment

April 5, 2023 By Sean Whooley

Glaukos iDose

Celanese (NYSE:CE) announced today that it entered into an agreement with Glaukos (NYSE:GKOS) over drug delivery for glaucoma treatments. Dallas-based Celanese agreed to supply its VitalDose drug delivery platform for use as a component in Gluakos’ iDose TR. The iDose TR serves as a micro-invasive intraocular implant for lowering intraocular pressure. It treats patients with […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Celanese, Glaukos

Glaukos submits FDA New Drug Application for iDose TR drug-eluting implant

February 27, 2023 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) announced today that it submitted a New Drug Application (NDA) to the FDA for its iDose TR implant. Aliso Viejo, California-based Glaukos designed iDose TR as a micro-invasive intraocular implant. It continuously delivers therapeutic levels of a proprietary formulation of travoprost from within the eye over extended periods of time. Once all travoprost […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Regulatory/Compliance, Technology Tagged With: FDA, Glaukos

Glaukos beats The Street in Q3

November 2, 2022 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Glaukos registered a deep bottom-line […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos

5 top ophthalmic device innovations you need to know

September 27, 2022 By Sean Whooley

Pixabay image of an eye to symbolize ophthalmic device innovations in the medtech medical device industry

Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Alcon, bausch&lomb, Clearside Biomedical, Glaukos, Johnson & Johnson, Johnson & Johnson Vision, Second Sight

Phase 3 trial data support Glaukos iDose eye drop alternative

September 7, 2022 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Pharmaceuticals Tagged With: Glaukos

FDA clears Glaukos’ iPrime

January 7, 2022 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced that it received FDA 510(k) clearance for its iPrime viscodelivery system. San Clemente, California-based Glaukos designed the iPrime viscodelivery system as a sterile, single-use, minimally invasive device for delivering viscoelastic fluid during ophthalmic surgery. Glaukos develops medical devices and pharmaceuticals centered around novel therapies for treating glaucoma, corneal disorders and retinal diseases. […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: FDA, Glaukos

Glaukos announces licensing deal with Attillaps for pharmaceutical compounds

September 20, 2021 By Sean Whooley

Glaukos Attillaps

Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Attillaps for its library of pharmaceutical compounds. San Clemente, California-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites — the root cause of Demodex […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: Attillaps, Glaukos

Ivantis to pay $60M in patent litigation settlement with Glaukos

September 15, 2021 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California, Southern Division, concerned Ivantis’ Hydrus Microstent for reducing eye pressure in glaucoma patients. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Implants, Legal News, Optical/Ophthalmic, Stents Tagged With: Glaukos, Ivantis

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS